Hyperfiltration in clinical practise


Cite item

Full Text

Abstract

Due to permanent increase of arterial hypertension prevalence and the frequency of hypertensive nephropathy development, as well as significant increase of cardiovascular complications risk after the appearance of microalbuminuria (MAU), special attention should be paid to patients with hyperfiltration, condition that leads to MAU development. The most common theory of hyperfiltration development is the theory of intact nephron. Methods of hyperfiltration detection includes instrumental and laboratory, predictive formulas for screening (e.g. Mayo), tests with protein upload. It is proven fact that hyperfiltration is associated with risk factors of metabolic syndrome. approaches for hyperfiltration correction are not standardized but established hyper activation of RAAS lets to offer ACE inhibitors and ARA as first line therapy

References

  1. Ермоленко В.М. Хроническая почечная недостаточность. В кн.: Нефрология. Руководство для врачей / Под ред. И.Е. Тареева. М., 1995. Т. 1. С. 322-390.
  2. Белоусов Ю.Б. Поражение органов мишеней при артериальной гипертонии // Терапевтический архив. 1997. №69(4). С. 12-15.
  3. Рогов В.А., Кутырина И.М., Тареева И.Е. и др. Функциональный резерв почек при нефротическом синдроме // Терапевтический архив. 1990. № 6. C. 55-58.
  4. Тареева И.Е., Николаев А.Ю., Лифшиц Н.Л. Диагностика и консервативное лечение хронической почечной недостаточности. Методические рекомендации для врачей. М., 1993.
  5. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992;36(Suppl.):S33-37.
  6. Моисеев В.С., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний) // Клиническая фармакология и терапия. 2002;11(3):16-18.
  7. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек // Терапевтический архив. 2004. № 6. С. 39-46.
  8. Мухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза // Терапевтический архив. 2007. № 6. С. 5-10.
  9. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-65.
  10. Yuyun MF, Khaw KT, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004;159:284-93.
  11. Cerasola G, Cottone S, Mule G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996;14(7):915-20.
  12. Lieb W, Mayer B, Stritzke J, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006;21(10):2780-87.
  13. Lekatsas I, Koulouris S, Triantafyllou K, et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int J Cardiol 2006;106(2):218-23.
  14. Szczudlik A, Turaj W, Slowik A, et al. Microalbuminuria and hyperthermia independently predict long-term mortality in acute ischemic stroke patients. Acta Neurol Scand 2003;107:96-101.
  15. Graninger M, Reiter R, Drucker C, et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004;44:335-39.
  16. Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens 2004;13:489-93.
  17. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-59.
  18. Diercks GF, Janssen WM, van Boven AJ, et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT). Am J Cardiol 2000;86:635-38.
  19. Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16.
  20. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of a cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249:519-26.
  21. Арутюнов Г.П. Патофизиологические процессы в почках у больных хронической сердечной недостаточностью // Сердечная недостаточность. 2008. Т. 9. № 5(49). С. 234-250.
  22. Makino H, Hironaka K, Shikata K, et al. Mesangial matrix act a mesangial channels to the juxtaglomerular zone. Nephron 1994;66:181-88.
  23. Gabbai FB. The glomerular capillary membrane a passive or active structure. J Lab Clin Med 1995;125:419-20.
  24. Maddox DA, Brenner BM. Glomerular ultrafiltration. In Brenner B.M. "The Kidney". W.B. Saunders CO 1991, chapter 6.
  25. Ruilope LM, Campo C, Rodriguez-Artalejo F, et al. Blood pressure and renal function: therapeutic implications. J Hypertens 1996;14:1259-63.
  26. Meyrier A, Simon P. Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant 1996;11:2116-20.
  27. Brenner MB, Meyer TW, Hostetter TH. Dietary protein intake and progressive nature of kidney disease: the role of hemodinamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis on aging, renal ablation and intrinsic renal disease. N Engl J Med 1982;307:652-59.
  28. Дмитрова Т.Б., Кобалава Ж.Д. Кардиоренальный синдром // РМЖ. 2003. Т. 11. № 12. С. 699.
  29. Sowers JR. Metabolic risk factors and renal disease. Kidney Int 2007;71:719-20.
  30. Hall JE, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324:127-37.
  31. Пермитина М.В., Белоусов Ю.В., Воробьева В.А. и др. Возможности ультразвукового метода исследования в выявлении диабетического поражения почек у детей и подростков // Российский ультразвуковой журнал "Эхография". 2003. Т. 4. № 2. С. 159-164.
  32. Архипов В.В., Папаян А.В., Береснева Е.А. Маркеры функции почек и оценка прогрессирования почечной недостаточности // Терапевтический архив. 2004. № 4. С. 83-90.
  33. Traynor J, Mactier R, et al. How to evaluate renal function in clinical practice? BMJ 2006;333(7571):733-37.
  34. Deinum J, Derkx FH. Cystatin for estimation of glomerular filtration rate? Lancet 2002;356:1624-25.
  35. Hellerstein S, Berenbom M, Alon US, et al. Creatinine clearance following cimetidine for estimation of glomerular filtration rate. Pediatr Nephrol 1998;12:49-54.
  36. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998;32:23-31.
  37. Арьев А.Л., Тараненко Е.А., Чистякова Ю.Г. Патент "Способ диагностики функционального почечного резерва". Медицинская Академия последипломного образования Коноваловой И.Г.
  38. Ратнер М.Я. Оценка почечных функций и классификация их расстройств при заболеваниях почек / В кн.: Ратнер М.Я., Серов В.В., Томилина Н.А. Ренальные дисфункции. М., 1977. C. 32-54.
  39. Клинические практические рекомендации по хроническому заболеванию почек: Оценка, Классификация и Стратификация, National Kidney Foundation K/DOQI, 2002.
  40. Моисеев В.С., Мухин Н.А., Кобалава Ж.Д. и др. Основные положения проекта рекомендаций Всероссийского научного общества кардиологов и научного общества нефрологов России по оценке функционального состояния почек у больных сердечно-сосудистыми заболеваниями или с повышенным риском их развития // Кардиоваскулярная терапия и профилактика. 2008. № 4.
  41. Cockrоft DW, Gault MH. Prediction of creatinine clearance from serum creatinine Nephron 1976;16:31-41.
  42. Gault MH, Longerich LL, Harnett JD, Wesolowski C: Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249-56.
  43. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84.
  44. Peterson JC, Adler S, Burkhart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
  45. Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996;27:652-63.
  46. Heymsfield SB, Arteaga C, McManus C, et al. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr 1983;37:478-94.
  47. Cohn SH, Abesemis C, Zanzi I, et al. Body elemental composition: comparison between black and white adults. Am J Physiol 1977;232:E419-22.
  48. Harsha DW, Frerichs RR, Berenson GS. Densitometry and anthropometry of black and white children. Hum Biol 1978;50:261-80.
  49. Worrall JG, Phongsathorn V, Hooper RJ. Racial variation in serum creatine kinase unrelated to lean body mass. Br J Rheumatol 1990;29:371-73.
  50. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996;7:556-65.
  51. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996;7:2097-109.
  52. Rule AD, Larson TS, Bergstralh Erik J, et al. Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease. © 2004 American College of Physicians 929.
  53. Rule AD, Cosio FG. The New Mayo Clinic Equation for Estimating Glomerular Filtration Rate. Ann Int Med 2005;142(8):681.
  54. Арьев А.Л. Возможности использования субмаксимального нагрузочного теста для оценки функционального состояния почек в практике ВТЭ. Организационно-методические вопросы социально-трудовой реабилитации инвалидов. Сборник научных трудов. Л., 1987. С. 45-50.
  55. Bosch JP, Saccagi A, Lauer A, et al. Renal functional reserve in humans. Effect of protein intake on glomerular rate. Am J Med 1983;75:943-50.
  56. Amiel C, Blanchet F, Friedlander G, et al. Renal functional reserve. Nephrol Dial Transplant 1990;5:763-70.
  57. Lindheimer MD, Lalone RC, Levinsky NG. Evidence that an acute increase in glomerular filtration has little effect in the dog unless extracellular volume in expanded. J Clin Invest 1967;46:256-65.
  58. Bosch JP, Lew S, Glabman S, et al. Renal hemodynamic changes in humans: response to protein loading in normal and diseased kidneys. Am J Med 1986;81:809-16.
  59. Hostetter TH. Renal hemodynamic response to a meat meal in humans. Kidney Int 1984;25:168.
  60. Поливода С.Н., Черепок А.А., Кулинич Р.Л. Оценка функционального состояния почек как предиктора эффективности антигипертензивной терапии у больных с гипертонической болезнью // Укр. кардіол. журн. 2005. № 3. С. 90-95.
  61. Мухин Н.А., Дедов И.И., Шестакова М.В. и др. Функциональные почечные резервы у больных сахарным диабетом // Терапевтический архив. 1990. № 2. С. 107-110.
  62. Sachman H, Tran-Van T, Tack I, et al. Contrasting renal functional reserve in very long-term type I diabetic patients with and without nephropathy. Diabetologia 2000;43:227-30.
  63. Gabbai FB. Renal reserve in patients with high blood pressure. Semin Nephrol 1995;15:482-87.
  64. Hostetter TM, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;9:85-93.
  65. Zitta S, Stoschitzky K, Zweiker R, et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. Nephrol Dial Transplant 2000;15(8):1162-69.
  66. Luca De Nicola, Blantz RC, Gabbai FB. Renal functional reserve in treated and untreated hypertensive rats. Kidney International 1991;40:406-12.
  67. Земченков А.Ю., Томилина Н.А. "К/ДОКИ" обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек) // Нефрология и диализ. 2004. Т. 6. № 3.
  68. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
  69. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:617-24.
  70. Jensen JS, Feldt-Rasmussen B, Strandgard S, et al. Arterial hypertension, microalbuminuria, and ischemic heart disease. Hypertension 2000;35:898-903.
  71. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004;17:986-93.
  72. De Jong PE, Hillege HL, Pinto-Sietsma SJ, et al. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant 2003;18:10-13.
  73. Redon J, Ruilope LM. Microalbuminuria as an intermediate endpoint in essential hypertension: evidence is coming. J Hypertens 2004;22:1679-81.
  74. Leoncini G, Sacchi G, Ravera M, et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002;16:399-404.
  75. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
  76. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
  77. Dahlquist G, Aperia A, Broberger O, et al. Renal function in relation to metabolic control in children with diabetes of different duration. ActaPaediatr Scand 1983;72:903-09.
  78. Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-71.
  79. Redon J, Rovira E, Miralles A, et al. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002;39:794-98.
  80. Диденко В.А. Показатели инсулинового обмена у больных артериальной гипертонией. В кн.: Сборник тезисов. Жуковский: ЦПДС Единение. 1999;89-90.
  81. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease and related disorders. Am J Hypertens 1993;6:S123-S134
  82. Sowers JR, Standley PR, Ram JL, et al. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993;6:S260-S270.
  83. Taskinen MR. Strategies for the diagnosis of metabolic syndrome. Cur Opin Lipid 1993;4:434-43.
  84. Зимин Ю.В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома X // Кардиология. 1998. № 6. С. 71-81.
  85. Hunsicker LG, Adler S, Cagguila A, et al. Predictors of the progressive association of cardiovascular risk factors with incident proteinuria. Arch Intern Med 2005;165:2299-304.
  86. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patient with incipient renal disease. Kidney Int 1998;53:1343-47.
  87. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-76.
  88. Jee SH, Bouware LB, Guallar E, et al. Direct,progressive association of cardiovascular risk factors with incident proteinuria. Arch Intern Med 2005;165:2299-04.
  89. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-40.
  90. Hsu C, McCulloch CE, Iribarran C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28.
  91. Tanaka H, Shiohira Y, Higa A, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006;69:369-74.
  92. Current Opinion in Nephrology & Hypertension. Obesity, proteinuria and progression of renal failure. Pharmacology and therapeutics 2006;15(5):481-86.
  93. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-76.
  94. Tomaszewski M, et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007;71:816-21.
  95. Chagnac A, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14:1480-86.
  96. Мухин Н., Козловская Л., Моисеев С. и др. Секреты метаболического синдрома. Клинический разбор в Клинике нефрологии, внутренних и профессиональных болезней им. Е.М. Тареева ММА им. И.М. Сеченова // Врач. 2005. № 4.
  97. Бутрова С.А. Синдром инсулинорезистентности при абдоминальном ожирении // Лечащий врач. 1999. № 7. С. 32-36.
  98. Кутырина И., Краснова Е., Федорова Е. и др. Поражение почек при ожирении: клинические, патогенетические и терапевтические аспекты // Врач. 2005. № 6.
  99. Saxena AK, Chopra R. Renal risk of an emerging epidemic of obesity: the role of adipocyte-derived factors. Nephrol Dial Transplant 2004;33:11-20.
  100. Кутырина И., Краснова Е., Федорова Е. и др. Поражение почек при ожирении: клинические, патогенетические и терапевтические аспекты // Врач. 2005. № 6.
  101. Chagnac A, Herman M, et al. P-333: Effect of obesity-induced hyperfiltration on renal peritubular capillary oncotic pressure. Am J Hypertens 2005;18:127A-127A; doi: 10.1016/j.amjhyper.2005.03.351.
  102. Сагинова Е.А., Федорова Е.Ю., Фомин В.В. и др. // Терапевтический архив. 2006. № 5.
  103. Baud L, Fouqueray B, Amrani PC. Tumor necrosis factor alpha and mesangial cells. Kidney Int 1992;41:600-03.
  104. Engeli S, Negel R, Sharma AM. Pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-76.
  105. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1996;1:2-26.
  106. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Intern 1997;52(Suppl. 63):124-27.
  107. Dengel DR, Glodberg AP, Mayuga RS, et al. Insulin resistance, elevated glomerular filtration fraction and renal injury. Hypertension 1996;28:127-32.
  108. Pichet R, Cantin M, Thibault G, et al. Hemodynamic and renal responses in physiological levels of ANF in conscious dog. Hypertens 1989;14:104-10.
  109. Gaillard CA, Mizelle HL, Mantani JP, et al. ANF and blood pressure control: role of sodium and aldosterone. Am J Physiol 1990;259:R973-980.
  110. Fenoy FJ, Quesada T, Garsi-Salom M, et al. Hemodynamic effects of chronic infusion of ANP in renal hypertensive rats. Am J Physiol 1989;256:H1393-1398.
  111. Chen HH, Pan S, Burnett JC, et al. A Novel Aquaretic and Glomerular Filtration Rate Enhancing Peptide Without Vascular Vasodilatory Actions in Experimental CHF. Circulation 2007;116:II61.
  112. Zhang PL, Mackenzie HS, Troy JL et al. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 1994;4:1564-70.
  113. Stuveling EM, Hillege HL, Bakker SJL, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population Kidney International 2003;63:654-61.
  114. Чазова И.Е., Ратова Л.Г.и др. Нефропротекция в лечении больных артериальной гипертонией (результаты исследования ИРИС) 2005. Т. 7. № 1.
  115. Mimran A. Renal function in hypertension. Am J Med 1988;84(Suppl. 1B):69-75.
  116. Whaley-Connell A, Sowers K, Sowers JR. Hypertension and cardiovascular disease. In: Cortes P, Mogensen CE (eds). Contemporary Diabetes: The Diabetic Kidney. Humana Press: Totowa, New Jersey 2006:497-511.
  117. Whaley-Connell AT, Chowdhury NA, Hayden MR, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006;291:F1308-F1314.
  118. Dzhusipov AK, Kistauova BZ, Ligay ZN, et al. Comparative estimation of eprosartan and fosinopril influence on renal hemodynamics in arterial hypertension patients. CIS Cardiology 2006;4(2).
  119. Agabiti-Rosei E, Ambrosioni E, Dal Palu C,et al. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995;13(11):1325-34.
  120. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes,myocardial infarction and stroke in high-risk patients. New Engl J Med 2000;342: 145-53.
  121. Pitt B. Potential role of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995;16:49-54.
  122. Подзолков В.И., Осадчий К.К. Сердечно-сосудистый континуум: могут ли ингибиторы АПФ разорвать "порочный круг"? // РМЖ. 2008. № 16.
  123. Hornig B. Effects of AT, receptor blockade on endothelial dysfunction. 2nd Intern. Forum on angiotenzin II receptor antagonism. Monte-Carlo 2001:18-19.
  124. Сагинова Е.А., Федорова Е.Ю., Фомин В.В Формирование поражения почек у больных // Терапевтический архив. 2006. Т. 78. № 5. С. 36-41.
  125. Zhong-Gao Xu, Lanting Linda, et al. Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney Circulation 2005;111:1962-69.
  126. Илларионова Т.С., Стуров Н.В., Чельцов В.В. Препараты, применяемые для лечения гипертонической болезни // РМЖ. Т. 15. № 28. C. 2124-2130.
  127. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundamental Clin Pharmacol 2007;21:181-90.
  128. Карпов Ю.А. Европейские рекомендации по артериальной гипертонии 2007 г.: блокаторы ангиотензиновых рецепторов усиливают позиции // РМЖ. 2007. Т. 15. № 20.
  129. Simons JL, Provoost AP, Anderson S, et al. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury, Kidney International 1994;46:396-404.
  130. Rojas M, Bell TD, Sturgis LS, et al. Blood Pressure Early in Diabetes Depends on a Balance Between Glomerular Filtration Rate and the Renin-Angiotensin System, Am J Hypertens 2006;19:1249-55.
  131. Белоусов Ю.Б., Моисеев В.С., Лепахин В.К. Клиническая фармакология и фармакотерапия. Руководство для врачей. 1993.
  132. Slomowitz LA, Peterson OW, Thomson SC. Baylor Converting Enzyme Inhibition and the Glomerular Hemodynamic Response to Glycine in Diabetic Rats. J Am Soc Nephrol 1999;10:1447-54.
  133. Томилина Н.А. Применение иАПФ в нефрологической клинике. Методические рекомендации № 17. М., 2000.
  134. Кутырина И.М. Лечение артериальной гипертонии при хронических заболеваниях почек // РМЖ. 1999. Т. 5. № 23.-С. 1535-1540.
  135. Bosch JP, Saccaggi A, Lauer A, et al. Renal functional reserve in humans. Am J Med 1983;75:943-49.
  136. Bochicchio T, Sandoval G, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives Kidney International 1990;38:873-879.
  137. Fliser D, Wagner K-K, Loos A, et al. Chronic Angiotensin II Receptor Blockade Reduces (Intra) Renal Vascular Resistance in Patients with Type 2 Diabetes. J Am Soc Nephrol 2005;16:1135-40.
  138. Delles C, Klingbeil AU, Schneider MP, et al. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension Am J Hypertens 2003;16:1030-35.
  139. Butler J, Forman DE, Abraham WT, et al. Relationship between HF treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-38.
  140. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients > 65 years of age with HF. Am J Card 2000;85:1110-13.
  141. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implication of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. JACC 2000;35(3):681-89.
  142. Smith GL, Vaccarino V, Kosiborod M, et al. Wosening renal function what is a clinically meaningful change in creatinine during hospitalization with HF. J Card Fail 2003;9:13-25.
  143. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive HF. J Card Fail 2002;8:136-41.
  144. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission and impact of worsening renal function among patients hospitalized with HF. JACC 2004;43:61-67.
  145. Semplicini A, Ceolotto G, Sartori M, et al. Regulation of glomerular transport and filtration in essential hypertension: role of abnormal Na atrial natriuretic peptide. J Nephrol 2002;15:489-96.
  146. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies